CDCA3 and glioma: MGMT promoter methylation was initially identified as a prognostic and predictive marker within the diagnosis of GBM in patients treated with temozolomide.[18] IDH is an independent factor indicating the prognosis of glioma patients.[19] Therefore, these results might suggest that glioma patients with high CDCA3 expression are not sensitive to temozolomide and have a poor prognosis.